Abstract
Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
CNS & Neurological Disorders - Drug Targets
Title:Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk
Volume: 15 Issue: 9
Author(s): Mohammad Nasser, Fabienne Bejjani, Mohamad Raad, Hadi Abou-El-Hassan, Sarah Mantash, Amaly Nokkari, Naify Ramadan, Nouhad Kassem, Stefania Mondello, Eva Hamade, Hala Darwish, Kazem Zibara and Firas Kobeissy
Affiliation:
Keywords: Biomarkers, blood-brain barrier, brain injury, connexins, cytokines, inflammation, neuronal injury, traumatic brain injury.
Abstract: Traumatic brain injury, often referred to as the “silent epidemic,” is a nondegenerative, non-congenital insult to the brain due to a blow or penetrating object that disrupts the function of the brain leading to permanent or temporary impairment of cognition, physical and psychosocial functions. Traumatic brain injury usually has poor prognosis for long-term treatment and is a major cause of mortality and morbidity worldwide; approximately 10 million deaths and/or hospitalizations annually are directly related to traumatic brain injury. Traumatic brain injury involves primary and secondary insults. Primary injury occurs during the initial insult, and results from direct or indirect force applied to the physical structures of the brain. Secondary injury is characterized by longer-term degeneration of neurons, glial cells, and vascular tissues due to activation of several proteases, glutamate and pro-inflammatory cytokine secretion. In addition, there is growing evidence that the blood-brain barrier is involved in the course of traumatic brain injury pathophysiology and has detrimental effects on the overall pathology of brain trauma, as will be discussed in this work.
Export Options
About this article
Cite this article as:
Nasser Mohammad, Bejjani Fabienne, Raad Mohamad, Abou-El-Hassan Hadi, Mantash Sarah, Nokkari Amaly, Ramadan Naify, Kassem Nouhad, Mondello Stefania, Hamade Eva, Darwish Hala, Zibara Kazem and Kobeissy Firas, Traumatic Brain Injury and Blood-Brain Barrier Cross-Talk, CNS & Neurological Disorders - Drug Targets 2016; 15 (9) . https://dx.doi.org/10.2174/1871527315666160815093525
DOI https://dx.doi.org/10.2174/1871527315666160815093525 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
G-Lymphatic, Vascular and Immune Pathways for Aβ Clearance Cascade and Therapeutic Targets For Alzheimer’s Disease
Combinatorial Chemistry & High Throughput Screening Ischemic Tolerance Induced by Normobaric Hyperoxia and Evaluation of Group I and II Metabotropic Glutamate Receptors
Current Neurovascular Research A Review on Deep Learning Architecture and Methods for MRI Brain Tumour Segmentation
Current Medical Imaging Antioxidants and Free Radical Scavengers for the Treatment Of Stroke, Traumatic Brain Injury and Aging
Current Medicinal Chemistry Advances in the Development of Bradykinin Receptor Ligands
Current Topics in Medicinal Chemistry Pulmonary Arterial Hypertension in HIV-infected Patients
Current Hypertension Reviews Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol
CNS & Neurological Disorders - Drug Targets New Molecular Targets in the Treatment of NSCLC
Current Pharmaceutical Design Inorganic Engineered Nanoparticles and Their Impact on the Immune Response
Current Drug Metabolism Trends in Snakebite Envenomation Therapy: Scientific, Technological and Public Health Considerations
Current Pharmaceutical Design In Models of Intracerebral Hemorrhage, Rivaroxaban is Superior to Warfarin to Limit Blood Brain Barrier Disruption and Hematoma Expansion
Current Neurovascular Research Gender Hormones: Role in the Pathogenesis of Central Nervous System Disease and Demyelination
Current Neurovascular Research Metal Complexes of Biologically Active Ligands as Potential Antioxidants
Current Medicinal Chemistry GABA Receptors: Pharmacological Potential and Pitfalls
Current Pharmaceutical Design Application of Microdialysis in Clinical Pharmacology
Current Clinical Pharmacology Review on Patents for Potent Anticoagulant Antithrombin-Heparin Covalent Complexes that Control Thrombosis In Vivo
Recent Patents on Biomedical Engineering (Discontinued) Nanoparticle-based Cerebral Drug-Delivery Systems and Antiangiogenic Approach in Gliomas Treatment
Recent Patents on Nanotechnology Lactoferricin Derived From Milk Protein Lactoferrin
Current Pharmaceutical Design The proNGF-p75NTR-Sortilin Signalling Complex as New Target for the Therapeutic Treatment of Parkinsons Disease
CNS & Neurological Disorders - Drug Targets Protein Kinase C Pharmacology: Perspectives on Therapeutic Potentials as Antidementic and Cognitive Agents
Recent Patents on CNS Drug Discovery (Discontinued)